Short Interest in Innate Pharma SA (OTCMKTS:IPHYF) Expands By 341.0%

Innate Pharma SA (OTCMKTS:IPHYF) was the target of a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 16,627 shares, a growth of 341.0% from the July 30th total of 3,770 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 10 shares, the days-to-cover ratio is currently 1,662.7 days.

Innate Pharma Price Performance

OTCMKTS:IPHYF remained flat at $1.65 during trading hours on Wednesday. The business’s fifty day moving average is $1.65 and its 200 day moving average is $1.75. Innate Pharma has a 1-year low of $1.37 and a 1-year high of $2.25.

Innate Pharma Company Profile

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.